Laroprovstat lowered LDL on rosuvastatin over 28 days in a phase 1 study. Safety was the primary objective; cardiovascular benefit and long-term safety remain unproven.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In the REAL8 SGA substudy, weekly somapacitan was noninferior to both daily GH doses at one year and superior only to the lower-dose comparator.
A pharmacokinetic crossover study and a four-week post hoc CAH subgroup analysis support biochemical effects, not established long-term clinical or safety benefits.
A 90-person trial found less weight regain with a specific pasteurised Akkermansia preparation over 24 weeks. Findings cannot be generalised to other supplements.
LIBerate-HoFH found variable LDL responses and did not establish lerodalcibep noninferiority to evolocumab at its prespecified margin. Read the PICO appraisal.
A 13-person crossover trial found higher ketone concentrations with dapagliflozin, without changing the primary GLP-1 endpoint. This is not a safety endorsement.
REAL8 found greater first-year height velocity with weekly somapacitan than daily GH in Noonan syndrome. Adult height and long-term safety remain separate questions.
BaxHTN found placebo-corrected systolic reductions of 8.7 and 9.8 mm Hg at 12 weeks. Review potassium events and why this differs from Bax24.
CARE-PWS did not meet its primary high-dose endpoints. Lower-dose hyperphagia findings were nominal secondary results, not a confirmatory efficacy success.
HISTORI tested semaglutide in schizophrenia with prediabetes and obesity. Review HbA1c and weight effects, gastrointestinal harms and psychiatric limitations.